FGL1 and colorectal carcinoma: Anti-FGL1 mAb treatment prolonged the survival of WT mice with liver metastasis of CRC; however, no significant differences in survival were observed between anti-FGL1 mAb–treated Cd8–/– mice and control IgG–treated Cd8–/– mice (left, Figure 10B) or between anti-FGL1 mAb–treated Nfil3–/– mice and control IgG–treated Nfil3–/– mice (right, Figure 10B), demonstrating that the antitumor efficacy of FGL1 blockade was abrogated in Cd8–/– mice or Nfil3–/– mice because of deficiency of CD8+ T cells or NK cells, respectively.